Connect with us

Business

Sanofi, GlaxoSmithKline start new COVID vaccine study

Published

on

Sanofi, GlaxoSmithKline start new COVID vaccine study

Sanofi and GlaxoSmithKline have launched a new study of their coronavirus vaccine after a previous trial produced disappointing results.

The drugmakers pushed back the rollout of their experimental COVID-19 shot in December because a study found it generated an “insufficient” immune response to the virus in people older than 50 years.

The companies have now tweaked the vaccine’s formulation and plan to test three different dosages in the new Phase 2 study of 720 adults in the US, Honduras and Panama, according to a Monday news release.

“We are confident that our vaccine candidate has strong potential and we are very encouraged by the latest preclinical data,” Thomas Triomphe, the head of Sanofi’s vaccine business, said in a statement. “This new Phase 2 study will enable us to identify the final vaccine formulation for adults of all ages.”

If the study goes well, Sanofi and GlaxoSmithKline plan to launch a large-scale Phase 3 trial in the spring and seek regulatory approval in the second half of this year.

The vaccine — which will be administered in two shots given three weeks apart in the Phase 2 study — would be made available in the final three months of 2021 if it’s approved, the European companies said.

Sanofi and GlaxoSmithKline are trailing other drugmakers in the race to distribute COVID-19 inoculations despite being two of the world’s biggest vaccine businesses.

Sanofi separately said Monday that it will help Johnson & Johnson manufacture its one-dose coronavirus vaccine, which is currently awaiting an emergency use authorization from the Food and Drug Administration.

Sanofi expects its factory in Marcy l’Etoile, France to churn out about 12 million doses of Johnson & Johnson’s shot per month.

The Paris-based company has also announced plans to help Pfizer and BioNTech produce more than 125 million doses of their vaccine, which is currently being distributed in the US.

Sanofi’s stock price dropped 0.2 percent in premarket trading Monday to $46.53 as of 7:39 a.m., while GlaxoSmithKline shares were recently trading roughly flat at $34.42.

Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

Philanthropist MacKenzie Scott marries Seattle science teacher

Published

on

By

Philanthropist MacKenzie Scott marries Seattle science teacher

MacKenzie Scott — the ex-wife of Amazon founder Jeff Bezos — has married a science teacher who works at a Seattle private school, according to a report.

Scott, one of the world’s richest women noted for her philanthropy, wed Dan Jewett, a teacher at Lakeside School, a source told the Wall Street Journal.

In a December blog post to Medium, Scott said she donated nearly $4.2 billion to charity in a span of four months to support struggling American during the COVID-19 pandemic.

Scott helped Bezos start Amazon in 1994. The two divorced in 2019.

Her Amazon author page currently says she “lives in Seattle with her four children and her husband, Dan,” the report said.

Continue Reading

Business

Boeing CEO waived pay but got compensation worth $21 million

Published

on

By

Boeing CEO waived pay but got compensation worth $21 million

Boeing CEO David Calhoun declined a salary and performance bonus for most of last year but still received stock benefits that pushed the estimated value of his compensation to more than $21 million, according to a regulatory filing Friday.

The aerospace giant struggled last year with the continuing fallout from two deadly crashes involving its 737 Max jetliner and a downturn in demand for planes because of the pandemic. Boeing lost nearly $12 billion and announced plans to cut about 30,000 jobs through layoffs and attrition.

Calhoun, who became CEO in January 2020, received $269,231 in salary for the period before he disavowed his salary in March. He also got $289,715 in other compensation, mostly perks such as the use of company planes, retirement benefits and home-security expenses.

The company said Calhoun gave up about $3.6 million by declining most of his salary and a $2.5 million bonus.

But most of Calhoun’s compensation — valued by Boeing at more than $20 million — came in the form of stock benefits that will vest in the next few years, assuming he remains CEO.

Those grants include $7 million worth of stock for returning the Max to service after it was grounded in 2019, $10 million worth of shares to compensate for pay he left behind at his previous job at The Blackstone Group, and $3.5 million in long-term incentive awards. All would vest over the next three years.

Calhoun, 63, was a longtime Boeing board member before being named CEO after the firing of Dennis Muilenburg in December 2019.

The Chicago-based company filed its proxy statement ahead of its April 20 annual shareholder meeting, which will be conducted online.

Shareholders will elect 10 directors. Pension funds in New York and Colorado are suing current and former board members and executives, including Calhoun and Muilenburg, in a Delaware state court. The funds accuse directors of lax safety oversight during the development of the 737 Max and after the first of two crashes that killed 346 people.

Continue Reading

Business

Tech rebound pulls stocks out of a slump and to weekly gain

Published

on

By

Tech rebound pulls stocks out of a slump and to weekly gain

Wall Street ended sharply higher after a volatile session Friday, with the Nasdaq rebounding at the end of a week that saw it extend losses to about 10 percent from its previous record high.

All three main indexes bounced back from losses earlier in the day, with investors in recent sessions spooked by rising interest rates that offset optimism about an economic rebound.

Microsoft rallied 2.15 percent, boosting the S&P 500 more than any other stock, with gains in Alphabet, Apple and Oracle also lifting the index.

The benchmark 10-year U.S. Treasury yields hit a new one-year high of 1.626 percent after nonfarm payrolls increased by 379,000 jobs last month, blowing past a rise of 182,000 forecast by economists polled by Reuters.

Focus is also on a $1.9 trillion coronavirus aid bill as a sharply divided U.S. Senate began what was expected to be a long debate over a slew of amendments on how that money would be spent.

The Nasdaq logged its third straight weekly decline after a recent spike in Treasury yields dented demand for high-flying technology stocks.

Rising interest rates disproportionately hurt high-growth tech companies because investors value them based on earnings expected years into the future, and high interest rates hurt the value of future earnings more than the value of earnings made in the short term.

The tech-heavy Nasdaq is around 8 percent below its Feb. 12 closing high.

Jake Dollarhide, chief executive officer of Longbow Asset Management in Tulsa, Oklahoma, said his firm in recent days has bought shares in a handful of growth companies whose prices have been pummeled in the recent selloff.

“Next week, I would expect volatility to continue, with pockets of opportunity, with certain things that sold off potentially rebounding,” Dollarhide said.

The Dow Jones Industrial Average rose 1.85 percent to end at 31,496.3 points, while the S&P 500 gained 1.95 percent to 3,841.94.

The Nasdaq Composite climbed 1.55 percent to 12,920.15.

In a busy session, volume on U.S. exchanges was 17.4 billion shares, compared with the 15.3 billion average for the full session over the last 20 trading days.

For the week, the S&P 500 rose 0.8 percent, the Dow added 1.8 percent and the Nasdaq lost 2.1 percent.

In Friday’s session, the S&P 500 energy sector index surged 3.9 percent to over a one year high as oil prices soared.

Oracle jumped more than 6 percent after Barclays upgraded the business software maker to “overweight” expecting improvement in the IT spending environment.

Advancing issues outnumbered declining ones on the NYSE by a 2.86-to-1 ratio; on Nasdaq, a 2.12-to-1 ratio favored advancers.

The S&P 500 posted 55 new 52-week highs and no new lows; the Nasdaq Composite recorded 225 new highs and 134 new lows.

Continue Reading

Trending